# Concord Drugs (NSE: CONCORD) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/CONCORD · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹101 Cr, it ranks 2675th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 2.2% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹38 Cr (+264.7% year on year) and net profit ₹1 Cr (+1,225.0%), on a consolidated basis. Promoters held 45.08% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹101 Cr |
| ROE | 2.2% (FY26) |
| ROCE | 5.9% (FY26) |
| Debt to equity | 0.28 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹38 Cr | +264.7% | ₹1 Cr | +1,225.0% | ₹0.47 |
| Q3 FY26 | ₹17 Cr | +57.1% | ₹0 Cr | −4.3% | ₹0.16 |
| Q2 FY26 | ₹10 Cr | −16.8% | ₹0 Cr | +375.0% | ₹0.19 |
| Q1 FY26 | ₹14 Cr | +16.4% | ₹0 Cr | +300.0% | ₹0.12 |
| Q4 FY25 | ₹10 Cr | −33.6% | ₹0 Cr | — | ₹0.04 |
| Q3 FY25 | ₹11 Cr | −15.5% | ₹0 Cr | — | ₹0.23 |
| Q2 FY25 | ₹12 Cr | +64.4% | ₹0 Cr | −92.9% | ₹0.04 |
| Q1 FY25 | ₹12 Cr | +30.2% | ₹0 Cr | −93.9% | ₹0.03 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹45 Cr | ₹0 Cr |
| FY24 | ₹45 Cr | ₹0 Cr |
| FY23 | ₹52 Cr | ₹1 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 45.08%
- Non-institutions: 54.92%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Mercury Labs](https://app.pivotnow.in/stock/MERCURYLAB) | — | ₹102 Cr | — | — |
| [Vaishali Pharma](https://app.pivotnow.in/stock/VAISHALI) | ₹7.49 | ₹101 Cr | 124.8 | — |
| [Denis Chem Lab](https://app.pivotnow.in/stock/DENISCHEM) | — | ₹101 Cr | — | — |
| [Fortis Malar](https://app.pivotnow.in/stock/FORTISMLR) | — | ₹97 Cr | — | — |
| [Raaj Medisafe](https://app.pivotnow.in/stock/RAAJMEDI) | — | ₹97 Cr | — | — |
| [KHFM HOSPITALIT](https://app.pivotnow.in/stock/KHFM) | ₹40.90 | ₹95 Cr | — | — |

## Questions and answers

### What is the market cap of Concord Drugs?

Concord Drugs' market capitalisation is ₹101 Cr (₹101 Cr) at the 22 Oct 2026 close, ranking 2675th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Concord Drugs?

Return on equity was 2.2% in FY26 and return on capital employed was 5.9% in FY26 (consolidated figures).

### Is Concord Drugs a debt-free company?

No. Concord Drugs' debt-to-equity ratio was 0.28 in FY26, with total debt of ₹2 Cr.

### What were Concord Drugs' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Concord Drugs reported revenue of ₹38 Cr, +264.7% year on year, and net profit of ₹1 Cr, +1,225.0% year on year.

### What is the shareholding pattern of Concord Drugs?

As of 30 Jun 2026: promoters 45.08%, non-institutions 54.92%.

### Who are Concord Drugs' competitors?

The listed Pharma & Healthcare companies closest to Concord Drugs by market cap are Mercury Labs, Vaishali Pharma, Denis Chem Lab, Fortis Malar, Raaj Medisafe and KHFM HOSPITALIT.

### Is Concord Drugs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Concord Drugs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CONCORD against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.